Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Theramex Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (19)
Cancellation by sponsor (18)
Prescription medicine registration (6)
Australian public assessment report (AusPar) (4)
Prescription medicine decision summary (2)

Date

2025 (1)
2024 (4)
2023 (5)
2022 (4)
2021 (11)
2020 (17)
2016 (1)
2011 (2)
2009 (1)
2007 (1)
2000 (2)

Search

Sponsor content

49 result(s) found, displaying 21 to 30

BIJUVA (Theramex Australia Pty Ltd)

27 April 2022

Prescription medicine registration

Active ingredients: estradiol hemihydrate, progesterone.
ATELVIA EC ONCE-A-WEEK risedronate sodium 35mg enteric-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 July 2021

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
AusPAR: Follitropin alfa

19 May 2021

Australian public assessment report (AusPar)

Australian Public Assessment Report for Follitropin alfa
Ovaleap

18 March 2021

Prescription medicine decision summary

TGA decision: Ovaleap (follitropin alfa) is approved to treat anovulatory infertility in woman who are unresponsive to clomiphene citrate.
OVALEAP (Theramex Australia Pty Ltd)

9 March 2021

Prescription medicine registration

Active ingredients: follitropin alfa.
Aventis Pharma Calcium Carbonate Tablet Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
aventis combination sachet Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ATELVIA risedronate sodium 5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ATELVIA risedronate sodium 30mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ATELVIA risedronate sodium 35mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.